Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
ESMO Open
|
May 26, 2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies
S B Maron, R-H Xu, Z A Wainberg, et al.
ESMO Open
|
May 7, 2025
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J Taieb, J Seligmann, D Modest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F Pietrantonio, R Miceli, L Rimassa, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study
G Mazzoli, F Nichetti, K Shitara, et al.
ESMO Open
|
September 6, 2024
Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series
J R Platt, J Allotey, E Alouani, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study
P Andena, G Tine, F Nichetti, et al.
ESMO Open
|
June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial
R Fazio, G Randon, F Bergamo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
P Ciracì, M M Germani, F Pietrantonio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
D Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
D Ciardiello, L Boscolo Bielo, S Napolitano, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
ESMO Open
|
May 26, 2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies
S B Maron, R-H Xu, Z A Wainberg, et al.
ESMO Open
|
May 7, 2025
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J Taieb, J Seligmann, D Modest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F Pietrantonio, R Miceli, L Rimassa, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study
G Mazzoli, F Nichetti, K Shitara, et al.
ESMO Open
|
September 6, 2024
Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series
J R Platt, J Allotey, E Alouani, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study
P Andena, G Tine, F Nichetti, et al.
ESMO Open
|
June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial
R Fazio, G Randon, F Bergamo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
P Ciracì, M M Germani, F Pietrantonio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
D Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
D Ciardiello, L Boscolo Bielo, S Napolitano, et al.
Page
of 8